Bullish & Foolish
Full OSTX fundamentals All 466 on the Survival Watch

OSTXOS THERAPIES INCORPORATED

Is OS Therapies struggling financially?

Yes, by its own account. OS Therapies told the SEC on 18 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

11/100

Critical

Sector
Biotech/Pharma
Market cap
$73.3M
Source filing
10-Q 18 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 0months

    If the burn speeds up

    Empty by Jun 2026

  • 1month

    If it eases off

    Empty by Jul 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$205K

÷

Cash burned over the last 12 months

$14.7M

What OS Therapies told the SEC

…vendor and related costs associated with these efforts to total approximately $ 20.0 million and continue into the remainder of 2026. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the unaudited consolidated financial statements are issued. The Company’s ability to continue as a going concern is dependent upon its ability to…

OS THERAPIES INCORPORATED, Form 10-Q, filed 18 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 65.0% share-count increase The company issued stock. Each share now owns 39.4% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt